玩股撇步(動畫小學堂)  

  • 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
  • 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近20季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
23Q4 (20)1200.8416.5-0.2725.048.08-0.2826.3239.13-1.30-25.027.370.490.48263.6485.4418.2633.54-0.423.0835.48-0.3321.4337.74-100.4855.8181.49-95.4156.1181.7922.87-6.73-7.21
23Q3 (19)1191.7115.53-0.36-38.4628.0-0.38-40.7413.64-1.04-50.7218.110.21-44.74110.072.25-15.01-14.12-0.52-100.014.75-0.42-40.019.23-227.36-260.6664.14-217.40-277.5664.49100.352.51-1.77
23Q2 (18)1174.4613.59-0.2643.4821.21-0.2737.216.9-0.69-50.010.390.38245.45533.3385.0116.45-3.17-0.2655.1738.1-0.341.1811.76-63.0488.1190.87-57.5888.7391.21122.7227.5121.87
23Q1 (17)1128.748.74-0.4611.54-6.98-0.436.52-13.16-0.4674.3-6.980.110.0120.073.0014.144.9-0.586.45-7.41-0.513.77-13.33-530.172.3649.99-510.762.549.825.003.770.98
22Q4 (16)1030.01.98-0.52-4.0-271.43-0.46-4.55-27.78-1.79-40.94-30.660.1110.0120.063.98-23.9513.92-0.62-1.64-26.53-0.53-1.92-278.57-542.9614.37-30.98-523.8714.42-26.3738.34-27.76-28.13
22Q3 (15)1030.00.98-0.50-51.52-28.21-0.44-51.72-46.67-1.27-64.94-3.250.166.67400.084.13-4.17288.67-0.61-45.24-69.44-0.52-52.94-33.33-634.098.267.31-612.156.5768.4443.34-14.13-14.02
22Q2 (14)1030.00.98-0.3323.2613.16-0.2923.680.0-0.77-79.079.410.0620.0500.087.7974.2671.5-0.4222.22-16.67-0.3424.4410.53-690.7334.8475.63-655.2335.6276.8810.00-91.949.06
22Q1 (13)1031.984.04-0.43-207.148.51-0.38-5.56-2.7-0.4368.618.510.050.0400.050.38-10.29-3.84-0.54-10.2-22.73-0.45-221.434.26-1060.06-155.7275.37-1017.83-145.5376.3575.00-71.52-12.78
21Q4 (12)101-0.9816.09-0.1464.161.11-0.36-20.0-50.0-1.37-11.3817.960.05150.0056.16225.952.37-0.49-36.11-68.97-0.1464.154.84-414.5478.6395.76-414.5478.6395.76125.0030.73-11.72
21Q3 (11)1020.010.87-0.39-2.6318.75-0.30-3.459.09-1.23-44.717.520.02100.0100.0-44.59-187.11-153.71-0.360.010.0-0.39-2.6311.36-1939.5931.5774.19-1939.5931.5774.1950.008.269.09
21Q2 (10)1023.0322.89-0.3819.1555.29-0.2921.6245.28-0.85-80.850.00.010.0051.19-2.29270.67-0.3618.1843.75-0.3819.1545.71-2834.3734.1580.39-2834.3734.1580.390.00-5.71-16.27
21Q1 (9)9913.7920.73-0.47-30.56-4.44-0.37-54.17-32.14-0.4771.86-4.440.010052.39-4.5628.12-0.44-51.72-29.41-0.47-51.61-27.03-4304.6056.0156.82-4304.6056.0156.82-50.00-2.78-13.45
20Q4 (8)87-5.437.41-0.3625.040.0-0.2427.2738.46-1.67-25.5616.920-100.0054.86-33.92163.82-0.2927.538.3-0.3129.5536.73-9785.27-30.228.39-9785.27-30.228.39-50.0034.2732.51
20Q3 (7)9210.8412.2-0.4843.532.04-0.3337.7410.81-1.33-56.474.320.010083.02501.16151.8-0.437.59.09-0.4437.14-10.0-7515.4548.0131.65-7515.4548.0131.650.00-22.68-25.78
20Q2 (6)831.223.75-0.85-88.897.61-0.53-89.2915.87-0.85-88.897.6100-100.013.81239.21-72.42-0.64-88.2415.79-0.7-89.195.41-14456.30-45.01-44.3-14456.30-45.01-44.30.00-31.95-30.54
20Q1 (5)821.230-0.4525.00-0.2828.210-0.4577.610000-9.9288.460-0.3427.660-0.3724.490-9968.9027.040-9968.9027.040--0.00
19Q4 (4)81-1.220.0-0.60-22.450.0-0.39-5.410.0-2.01-44.60.0000.0-85.96-360.720.0-0.47-6.820.0-0.49-22.50.0-13663.80-24.260.0-13663.80-24.260.0--0.00
19Q3 (3)822.50.0-0.4946.740.0-0.3741.270.0-1.39-51.090.00-100.00.032.97-34.150.0-0.4442.110.0-0.445.950.0-10996.20-9.760.0-10996.20-9.760.0--0.00
19Q2 (2)8000.0-0.9200.0-0.6300.0-0.9200.00.0100.050.0700.0-0.7600.0-0.7400.0-10018.1000.0-10018.1000.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/30.1582.37262.240.35227.270.35N/A係銷售醫療器材及保健食品、抗生素之收入
2024/20.08-27.66212.790.2204.740.31N/A係銷售醫療器材及保健食品、抗生素之收入
2024/10.125.6199.170.12199.170.32N/A係銷售醫療器材及保健食品、抗生素之收入
2023/120.1119.2204.621.09245.440.380.45係銷售醫療器材、保健食品、抗生素之收入及簽約金收入
2023/110.09-48.4294.290.98250.740.340.5係銷售醫療器材及保健食品、抗生素之收入、技術授權收入
2023/100.18162.89581.750.88282.950.320.54係銷售醫療器材及保健食品、抗生素之收入、技術授權收入
2023/90.07-2.82147.540.7244.590.210.71係銷售醫療器材、保健食品、抗生素之收入及簽約金收入
2023/80.07-5.16104.010.64259.670.20.77係銷售醫療器材及保健食品、抗生素之收入、簽約金收入
2023/70.0742.82141.970.57297.140.410.36係銷售醫療器材及保健食品、抗生素之收入、簽約金收入
2023/60.05-81.99109.130.49339.40.380.42係銷售醫療器材及保健食品、抗生素之收入、簽約金收入
2023/50.29530.561393.030.44404.570.380.43係銷售醫療器材、保健食品、抗生素之收入及簽約金收入
2023/40.057.67160.010.15125.410.111.39係銷售醫療器材及保健食品、抗生素之收入
2023/30.0457.47197.050.11113.430.111.11係銷售醫療器材及保健食品、抗生素之收入
2023/20.03-30.8193.650.0780.670.11.18係銷售醫療器材及保健食品、抗生素之收入
2023/10.047.5272.660.0472.660.120.98係銷售醫療器材及保健食品、抗生素之收入
2022/120.04-23.96127.230.31239.250.110.45係銷售醫療器材及保健食品、抗生素之收入
2022/110.0580.95185.230.28262.450.10.49係銷售醫療器材及保健食品、抗生素之收入
2022/100.03-4.5469.20.23283.850.090.57係銷售醫療器材及保健食品、抗生素之收入
2022/90.03-19.91163.750.2358.520.090.87係銷售醫療器材及保健食品、抗生素之收入
2022/80.0312.47769.620.18417.960.090.89係銷售醫療器材及保健食品、抗生素之收入
2022/70.0323.44421.160.14372.010.071.07係銷售醫療器材及保健食品、抗生素之收入
2022/60.0228.51539.270.11360.190.060.98係銷售醫療器材及保健食品、抗生素之收入
2022/50.029.81612.960.09326.390.051.18係銷售醫療器材及保健食品、抗生素之收入
2022/40.0223.01153.320.07282.920.051.31係銷售醫療器材及保健食品、抗生素之收入
2022/30.012.66152.650.05365.340.051.38係銷售醫療器材及保健食品、抗生素之收入
2022/20.01-38.31259.580.04522.940.051.34係銷售醫療器材及保健食品、抗生素之收入
2022/10.0241.51530.430.021530.430.061.27係銷售醫療器材及保健食品、抗生素之收入
2021/120.02-4.56952.980.09565.390.051.87係銷售醫療器材及保健食品、抗生素之收入
2021/110.027.345453.330.08518.270.042.11係銷售醫療器材及保健食品、抗生素之收入
2021/100.0248.81024.630.06396.120.033.01係銷售醫療器材及保健食品、抗生素之收入
2021/90.01164.05485.950.04315.360.024.94係銷售醫療器材及保健食品、抗生素之收入
2021/80.0-32.592368.750.03281.470.017.31係銷售醫療器材及保健食品、抗生素之收入。
2021/70.0151.4248.350.03243.520.018.05係銷售醫療器材及保健食品、抗生素之收入
2021/60.043.33706.250.02402.470.019.64係銷售醫療器材及保健食品、抗生素之收入
2021/50.0-60.98938.460.02368.030.028.52係銷售醫療器材及保健食品、抗生素之收入
2021/40.0122.691674.350.02332.030.027.92係銷售醫療器材及保健食品、抗生素之收入暨權利金收入
2021/30.0146.11705.710.01191.680.0111.95係銷售醫療器材及保健食品、抗生素之收入
2021/20.0179.7127.390.0192.730.0119.26係銷售醫療器材及保健食品、抗生素之收入
2021/10.0-8.60.00.00.00.040.75係銷售保健食品及抗生素之收入
2020/120.0403.330.00.0117.250.031.35係銷售保健食品及抗生素之收入及銷售組織處理器之權利金收入
2020/110.0-78.26-90.250.014.540.028.9係銷售保健食品及抗生素之收入
2020/100.0-22.470.00.0137.720.030.12係銷售保健食品及抗生素之收入
2020/90.01012.50.00.0122.040.0115.28係銷售保健食品及抗生素之收入
2020/80.0-95.940.00.011.810.019.61係銷售保健食品及手術器械組之收入
2020/70.0722.9125.790.0125.710.019.19係銷售保健食品及手術器械組之收入
2020/60.084.610.00.025.640.044.25係銷售保健食品及銷售組織處理器之權利金收入
2020/50.0-33.330.00.013.470.037.04係銷售保健食品之收入。
2020/40.0-44.280.00.06.730.012.14係銷售保健食品之收入。
2020/30.0-76.890.00.0-3.360.08.04係銷售組織處理器之權利金收入。
2020/20.00.00.00.0-21.50.09.9係銷售組織處理器產生之營收。
2020/10.00.0-100.00.0-100.00.09.74去年本月係銷售組織處理器產生之營收。
2019/120.0-100.00.00.010.00.09.74係產品銷售收入
2019/110.00.00.00.010.00.09.74係產品銷售收入
2019/100.00.00.00.010.00.00係產品銷售收入
2019/90.00.00.00.010.00.06.37係產品銷售收入
2019/80.0-100.00.00.010.00.06.37係產品銷售收入
2019/70.00.00.00.010.00.06.37係產品銷售收入
2019/60.00.00.00.00.00.00係產品銷售收入
2019/50.00.00.00.00.00.0N/A-
2019/40.00.00.00.00.00.0N/A-
成長能力-近10年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2023 (10)12016.5-1.300-1.3601.1254.8481.5412.56-1.770-1.690-1.560
2022 (9)1031.98-1.790-1.5700.31244.4472.44119.52-2.190-2.140-1.840
2021 (8)10116.09-1.370-1.3200.09800.033.00-37.12-1.640-1.440-1.380
2020 (7)877.41-1.670-1.1200.010.052.48314.53-1.340-1.460-1.460
2019 (6)8132.79-2.010-1.3900.01012.660-1.670-1.630-1.630
2018 (5)6141.86-2.760-1.380000.000-1.660-1.670-1.670
2017 (4)4372.0-2.980-1.130000.000-1.440-1.380-1.30
2016 (3)2500.000-0.570000.000-0.680-0.680-0.680

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。